Skip to content

Feasibility of Emotion Regulation Group Therapy for Adolescent Self-Harm

Can a Brief Emotion Regulation Group Therapy Help Adolescents With Deliberate Self-Harm? A Feasibility Study and a Qualitative Interview Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06297824
Acronym
ERGT-A
Enrollment
21
Registered
2024-03-07
Start date
2023-10-10
Completion date
2025-03-10
Last updated
2025-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent - Emotional Problem, Emotion Regulation, Self-harm

Keywords

self-harm, Emotion regulation, Group treatment, Adolescents

Brief summary

Deliberate self-harm (DSH) is a prevalent behaviour among adolescents but there is no current recommendation for an efficacious treatment. Emotion regulation group therapy (ERGT) is a brief treatment for DSH with a well-documented utility and feasibility in the adult population, and an adapted version for adolescents may provide equal benefits for adolescents, provided adjustments to prevent or decrease social contagion are present. A quantitative feasibility open trial (N=20) followed up by a qualitative interview study will examine the feasibility, acceptability and preliminary effect of ERGT for adolescents.

Detailed description

Deliberate self-harm (DSH) is a prevalent behaviour among adolescents but there is no current recommendation for an efficacious treatment. Emotion regulation group therapy (ERGT) is a brief treatment for DSH with a well-documented utility and feasibility in the adult population, and an adapted version for adolescents may provide equal benefits for adolescents, provided adjustments to prevent or decrease social contagion are present. Adaptations to ERGT will result in a 12 session long treatment for adolescents Emotion regulation group therapy for Adolescents (ERGT-A). A parallel parent group focused on strengthening parental skills will be given alongside ERGT-A (5 sessions) Method: A quantitative feasibility open trial (N=20) with pre, post and 1 month follow-up assessments will examine the feasibility, acceptability and preliminary effect of ERGT for adolescents. Feasibility measures include recruitment rate, proportion beginning treatment, attrition, treatment credibility and satisfaction, negative effects, and alliance. Preliminary effects measures include DSH, emotion regulation ability, anxiety and depression. Method: A qualitative interview study. Using thematic analysis to explore participants' experience of ERGT-A and parent group

Interventions

BEHAVIORALERGT-A

Emotion regulation group therapy for adolescents

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Feasibility, open trial

Eligibility

Sex/Gender
ALL
Age
13 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1. 13-17 years of age; 2. having engaged in deliberate self-harm (DSH)-behaviours ≥ 5 times the last year; 3. having engaged in ≥1 DSH episode during the past month; 4. having ongoing psychiatric treatment in the community; 5. having at least one caregiver or other significant adult, committed to participate in the parent program; and 6. stability of psychotropic medications

Exclusion criteria

1. a diagnosis of psychotic, bipolar I disorder or severe social anxiety disorder (SAD); 2. ongoing substance dependence; 3. the presence of co-occurring psychiatric disorders that require immediate treatment; 4. having an autism spectrum disorder together with borderline intellectual disability or having an intellectual disability; 5. insufficient understanding of the Swedish language

Design outcomes

Primary

MeasureTime frameDescription
Feasibility measures, negative effects of treatmentat post-treatment EOT (12 weeks)Low rating on Negative effects Questionnaire (lower= better, min 0-max 20)
Feasibility measures, proportion includedthrough study completion, an average of 1 yearProportion of participants invited to participate who accepts and is included (higher = better, min 0%- max 100%)
Feasibility measures, compliancePre-treatment to post-treatment (End of treatment, EOT) (12 weeks)Compliance, no of sessions attended (\>50%), (higher = better, min 0-max 10)
Feasibility measures, attritionPre-treatment to post-treatment EOT (12 weeks)Attrition, percent of included participants who drops out of treatment (lower = better, min 0%- max 100%)
Feasibility measures, client satisfactionat post-treatment EOT (12 weeks)Mean score on Client satisfaction questionnaire\> 25 (higher= better, min 8-max 32)
Feasibility measure, recruitment ratethrough study completion, an average of 1 yearRecruitment rate

Secondary

MeasureTime frameDescription
Preliminary effect, self harm frequency 1MFUPost-treatment (EOT) to follow-up (4 weeks)Mean Deliberate self-harm frequency at post-treatment and 1MFU lower than at post-treatment (min 0-max 100, lower=better)
Preliminary effect, emotion dysregulation EOTPre-treatment to post-treatment (EOT) (12 weeks)Mean difficulty in emotion regulation rating (DERS-16) at post-treatment lower than at pre-treatment (min 16, max 80, lower=better)
Preliminary effect, emotion dysregulation 1MFUPost-treatment (EOT) to follow-up (4 weeks)Mean difficulty in emotion regulation rating (DERS-16) at 1MFU lower than at post-treatment (min 16, max 80, lower=better)
Preliminary effect, self harm frequency EOTPre-treatment to post-treatment (EOT) (12 weeks)Mean Deliberate self-harm frequency at post-treatment (min 0-max 100, lower=better)

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026